Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab in Treating Patients With Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
- Status
- COMPLETED
- Phase
- PHASE2